Phagosomal granulocytic ROS in septic patients induce the bacterial SOS response.

Autor: Chollet S; University Limoges, Inserm, CHU Limoges, RESINFIT, U 1092, F-87000 Limoges, France., Hernandez Padilla AC; University Limoges, Inserm, CHU Limoges, RESINFIT, U 1092, F-87000 Limoges, France., Daix T; University Limoges, Inserm, CHU Limoges, RESINFIT, U 1092, F-87000 Limoges, France.; CHU Limoges, Service de Réanimation Polyvalente, Limoges, France.; Inserm CIC 1435, Limoges, France., Gaschet M; University Limoges, Inserm, CHU Limoges, RESINFIT, U 1092, F-87000 Limoges, France., François B; University Limoges, Inserm, CHU Limoges, RESINFIT, U 1092, F-87000 Limoges, France.; CHU Limoges, Service de Réanimation Polyvalente, Limoges, France.; Inserm CIC 1435, Limoges, France., Piguet C; CHU Limoges, Département de pédiatrie médicale, Limoges, France., Gachard N; CHU Limoges, Laboratoire d'hématologie, Limoges, France.; CNRS UMR 7276, Inserm UMR 1262, Université de Limoges, Limoges, France., Da Re S; University Limoges, Inserm, CHU Limoges, RESINFIT, U 1092, F-87000 Limoges, France., Jeannet R; Inserm CIC 1435, Limoges, France.; CNRS UMR 7276, Inserm UMR 1262, Université de Limoges, Limoges, France., Ploy MC; University Limoges, Inserm, CHU Limoges, RESINFIT, U 1092, F-87000 Limoges, France.

Publikováno v: IScience [iScience] 2024 Apr 26; Vol. 27 (6), pp. 109825. Date of Electronic Publication: 2024 Apr 26 (Print Publication: 2024).

Perpetual observational studies: new strategies to support efficient implementation of observational studies and randomized trials in infectious diseases.

Autor: Hassoun-Kheir N; Infection Control Program, Geneva University Hospitals and Faculty of Medicine, Geneva Switzerland., van Werkhoven CH; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, the Netherlands., Dunning J; Pandemic Sciences Institute, University of Oxford, Oxford, UK., Jaenisch T; Heidelberg Institute of Global Health (HIGH), Heidelberg University Hospital, Heidelberg, Germany., van Beek J; Department of Viroscience, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands., Bielicki J; Institute for Infection and Immunity, St George's, University of London, London, UK; Infection Prevention and Control, Universitäts-Kinderspital Beider Basel, Basel, Switzerland., Butler CC; Nuffield Department of Primary Care Health Sciences, Oxford University., Francois B; Medical-Surgical Intensive Care Unit and Inserm CIC 1435 & UMR 1092, CHU Limoges, Limoges, France., Harbarth S; Infection Control Program, Geneva University Hospitals and Faculty of Medicine, Geneva Switzerland., Hernandez Padilla AC; Medical-Surgical Intensive Care Unit and Inserm CIC 1435 & UMR 1092, CHU Limoges, Limoges, France., Horby P; Pandemic Sciences Institute, University of Oxford, Oxford, UK., Koopmans M; Department of Viroscience, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands; Pandemic and Disaster Preparedness Research Centre, Rotterdam, the Netherlands., Lee J; Pandemic Sciences Institute, University of Oxford, Oxford, UK., Rodriguez-Baño J; Infectious Diseases and Microbiology, Hospital Universitario Virgen Macarena, Department of Medicine, University of Sevilla, Biomedicine Institute of Sevilla (IBiS), CSIC, Sevilla, Spain; Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain., Tacconelli E; Department of Infectious Diseases, University of Verona, Verona, Italy., Themistocleous Y; Pandemic Sciences Institute, University of Oxford, Oxford, UK., van der Velden AW; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, the Netherlands., Bonten M; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, the Netherlands., Goossens H; Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium., de Kraker MEA; Infection Control Program, Geneva University Hospitals and Faculty of Medicine, Geneva Switzerland. Electronic address: marlieke.dekraker@hcuge.ch.

Publikováno v: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases [Clin Microbiol Infect] 2022 Dec; Vol. 28 (12), pp. 1528-1532. Date of Electronic Publication: 2022 Aug 05.

High prevalence of infections in non-COVID-19 patients admitted to the Emergency Department with severe lymphopenia.

Autor: Baïsse A; Emergency Department, Limoges University Hospital Center, 2 avenue Martin Luther King, 87042, Limoges, France., Daix T; Inserm CIC 1435, Limoges University Hospital Center, 87042, Limoges, France.; Medical-Surgical Intensive Care Unit, Limoges University Hospital Center, 87042, Limoges, France.; Inserm UMR 1092, University of Limoges, 87042, Limoges, France., Hernandez Padilla AC; Inserm CIC 1435, Limoges University Hospital Center, 87042, Limoges, France., Jeannet R; CNRS UMR 7276 / INSERM U 1262, University of Limoges, Limoges, France., Barraud O; Inserm UMR 1092, University of Limoges, 87042, Limoges, France.; CNRS UMR 7276 / INSERM U 1262, University of Limoges, Limoges, France.; Microbiology Department, Limoges University Hospital Center, 87042, Limoges, France., Dalmay F; Inserm UMR 1094, University of Limoges, 87042, Limoges, France., François B; Inserm CIC 1435, Limoges University Hospital Center, 87042, Limoges, France.; Medical-Surgical Intensive Care Unit, Limoges University Hospital Center, 87042, Limoges, France.; Inserm UMR 1092, University of Limoges, 87042, Limoges, France., Vignon P; Inserm CIC 1435, Limoges University Hospital Center, 87042, Limoges, France.; Medical-Surgical Intensive Care Unit, Limoges University Hospital Center, 87042, Limoges, France.; Inserm UMR 1092, University of Limoges, 87042, Limoges, France., Lafon T; Emergency Department, Limoges University Hospital Center, 2 avenue Martin Luther King, 87042, Limoges, France. Thomas.LAFON@chu-limoges.fr.; Inserm CIC 1435, Limoges University Hospital Center, 87042, Limoges, France. Thomas.LAFON@chu-limoges.fr.

Publikováno v: BMC infectious diseases [BMC Infect Dis] 2022 Mar 26; Vol. 22 (1), pp. 295. Date of Electronic Publication: 2022 Mar 26.

Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.

Autor: François B; ICU Department, Inserm CIC-1435 and UMR-1092, CRICS-TRIGGERSEP Network, CHU Dupuytren, Limoges, France. Electronic address: b.francois@unilim.fr., Jafri HS; BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA. Electronic address: hasan.jafri.md@gmail.com., Chastre J; Institut de Cardiologie, Service de Réanimation Médicale, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France., Sánchez-García M; Department of Critical Care, Hospital Clínico San Carlos, Madrid, Spain., Eggimann P; Department of Critical Care, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland., Dequin PF; CHRU de Tours, Service de Médecine Intensive Réanimation, Inserm CIC 1415 and UMR-1100, and CRICS-TRIGGERSEP Network, Tours, France., Huberlant V; Centre Hospitalier Jolimont-Lobbes, La Louvière, Belgium., Viña Soria L; Hospital Universitario Central de Asturias, Asturias, Spain., Boulain T; Centre Hospitalier Régional d'Orléans, Médecine Intensive Réanimation, Orleans, France., Bretonnière C; Service de Soins Intensifs-Pneumologie, Hôpital Guillaume et René Laennec, Nantes, France., Pugin J; Département d'Anesthésiologie, Pharmacologie, Soins Intensifs et Urgences, Université de Genève, Geneva, Switzerland., Trenado J; Intensive Care Department, Hospital Universitari Mutua de Terrassa, Terrassa, Spain., Hernandez Padilla AC; CHU Limoges and Inserm UMR-1092, Limoges, France., Ali O; BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Shoemaker K; BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Ren P; BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Coenjaerts FE; Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands., Ruzin A; BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Barraud O; CHU Limoges and Inserm UMR-1092, Limoges, France., Timbermont L; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, Antwerp University Hospital, Antwerp, Belgium., Lammens C; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, Antwerp University Hospital, Antwerp, Belgium., Pierre V; BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Wu Y; BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Vignaud J; CHU Limoges and Inserm UMR-1092, Limoges, France., Colbert S; BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Bellamy T; BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Esser MT; BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Dubovsky F; BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Bonten MJ; Department of Medical Microbiology and Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands., Goossens H; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, Antwerp University Hospital, Antwerp, Belgium., Laterre PF; Intensive Care Unit, Université Catholique de Louvain, Louvain-la-Neuve, Belgium.

Publikováno v: The Lancet. Infectious diseases [Lancet Infect Dis] 2021 Sep; Vol. 21 (9), pp. 1313-1323. Date of Electronic Publication: 2021 Apr 21.

Is prehospital endobronchial intubation a risk factor for subsequent ventilator associated pneumonia? A retrospective analysis.

Autor: Hernandez Padilla AC; INSERM CIC 1435, CHU Dupuytren, Limoges, France., Trampont T; Service d'Accueil des Urgences, CHU Dupuytren, Limoges, France., Lafon T; INSERM CIC 1435, CHU Dupuytren, Limoges, France.; Service d'Accueil des Urgences, CHU Dupuytren, Limoges, France., Daix T; INSERM CIC 1435, CHU Dupuytren, Limoges, France.; Réanimation polyvalente, CHU Dupuytren, Limoges, France.; INSERM UMR 1092, Université Limoges, Limoges, France., Cailloce D; SAMU/SMUR, CHU Dupuytren, Limoges, France., Barraud O; INSERM UMR 1092, Université Limoges, Limoges, France.; Laboratoire de Bactériologie-Virologie-Hygiène, CHU Dupuytren, Limoges, France., Dalmay F; INSERM UMR 1094, Université Limoges, Limoges, France., Vignon P; INSERM CIC 1435, CHU Dupuytren, Limoges, France.; Réanimation polyvalente, CHU Dupuytren, Limoges, France., François B; INSERM CIC 1435, CHU Dupuytren, Limoges, France.; Réanimation polyvalente, CHU Dupuytren, Limoges, France.; INSERM UMR 1092, Université Limoges, Limoges, France.

Publikováno v: PloS one [PLoS One] 2019 May 23; Vol. 14 (5), pp. e0217466. Date of Electronic Publication: 2019 May 23 (Print Publication: 2019).